Mineralocorticoid Receptor and Obesity Induced Cardiovascular Complications

Brigham and Women's Hospital38 enrolled

Overview

The purpose of this study is to find out if spironolactone, a drug that blocks the action of aldosterone, can make the blood vessels work better in people with obesity. The investigators also want to find out whether spironolactone causes changes in levels of insulin and markers of inflammation.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

TRIPLE

Enrollment

Conditions

Obesity Insulin Resistance

Interventions

SpironolactoneDRUG

50 mg once daily for 6 weeks.

PlaceboDRUG

Placebo-matching spironolactone once daily for 6 weeks.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Age 18-70 years 2. Good health as evidenced by history and physical exam 3. Body Mass Index (BMI): \>30 kg/m2 and \<45 kg/m2 Exclusion criteria: 1. Medical illnesses other than treated hypothyroidism 2. Blood Pressure (BP) \>135/85 or systolic BP \<90 mm Hg 3. Hepatic disease (transaminase \> 3 times normal) 4. Renal impairment (Creatinine clearance \<60 ml/min) 5. Baseline serum Potassium (K) \>5.0 mmol/L 6. History of drug or alcohol abuse 7. Allergies to spironolactone 8. Participation in any other concurrent clinical trial 9. Women using oral contraceptives within the last 3 months

Locations (1)

Brigham and Women's Hospital

Boston, Massachusetts, United States

Outcomes

Primary Outcomes

Change From Baseline in Post-ischemic Dilatation

Ultrasonography of the brachial artery was performed to evaluate endothelial function by flow mediated dilatation (FMD) studies. A blood pressure cuff was placed on the participant's upper arm and was compressed for 5 minutes. After release of compression, brachial artery diameter and blood flow velocity were measured. FMD was expressed as the percentage change in brachial artery diameter. A positive change from Baseline indicates improvement.

Time frame: Baseline and Week 6

Secondary Outcomes

Change From Baseline in Para-aminohippurate (PAH) Clearance

Renal plasma blood flow was determined by clearance of para-aminohippurate (PAH). A loading dose of PAH (8 mg/kg) was given intravenously followed by a 1 hour constant infusion of PAH at a rate of 12 mg/minute (min). Plasma samples were obtained at Baseline and at 50 and 60 minutes. PAH clearance was calculated from the plasma levels and infusion rates and reported in millimeters (mL)/minute (min). A positive change from Baseline indicates improvement.

Time frame: Baseline and Week 6 (Prior to PAH infusion and at 50 and 60 minutes post PAH infusion)

Change From Baseline in Markers of Inflammation

Blood was to be collected and tested for Tumor Necrosis Factor Alpha (TNF-α) and Monocyte Chemotactic Protein-1 (MCP-1), markers of inflammation; However, due to lack of funding, blood samples were not analyzed and data for levels of inflammation markers were not collected.

Time frame: Baseline and Week 6

Change From Baseline in Insulin Sensitivity Index (ISI)

Insulin sensitivity was measured using the 75 gram (G) glucose tolerance test. Participants ingested 75 grams of glucose in 300-400 milliliters (mL) of water over 5 minutes. Blood samples were taken before ingesting glucose and then every 30 minutes for 120 minutes. Insulin sensitivity index was calculated by Matsuda and Defronzo's formula using the values obtained. A positive change from Baseline (increase in insulin sensitivity) indicates improvement.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.